Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...